Cargando…

Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake Among People Living With Human Immunodeficiency Virus

BACKGROUND: High costs of direct-acting antivirals (DAAs) have led health-care insurers to limit access worldwide. Using a natural experiment, we evaluated the impact of removing fibrosis stage restrictions on hepatitis C (HCV) treatment initiation rates among people living with human immunodeficien...

Descripción completa

Detalles Bibliográficos
Autores principales: Saeed, Sahar, Strumpf, Erin, Moodie, Erica E M, Wong, Leo, Cox, Joseph, Walmsley, Sharon, Tyndall, Mark, Cooper, Curtis, Conway, Brian, Hull, Mark, Martel-Laferriere, Valerie, Gill, John, Wong, Alexander, Vachon, Marie-Louise, Klein, Marina B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7353326/
https://www.ncbi.nlm.nih.gov/pubmed/31504327
http://dx.doi.org/10.1093/cid/ciz833
_version_ 1783557850029621248
author Saeed, Sahar
Strumpf, Erin
Moodie, Erica E M
Wong, Leo
Cox, Joseph
Walmsley, Sharon
Tyndall, Mark
Cooper, Curtis
Conway, Brian
Hull, Mark
Martel-Laferriere, Valerie
Gill, John
Wong, Alexander
Vachon, Marie-Louise
Klein, Marina B
author_facet Saeed, Sahar
Strumpf, Erin
Moodie, Erica E M
Wong, Leo
Cox, Joseph
Walmsley, Sharon
Tyndall, Mark
Cooper, Curtis
Conway, Brian
Hull, Mark
Martel-Laferriere, Valerie
Gill, John
Wong, Alexander
Vachon, Marie-Louise
Klein, Marina B
author_sort Saeed, Sahar
collection PubMed
description BACKGROUND: High costs of direct-acting antivirals (DAAs) have led health-care insurers to limit access worldwide. Using a natural experiment, we evaluated the impact of removing fibrosis stage restrictions on hepatitis C (HCV) treatment initiation rates among people living with human immunodeficiency virus (HIV), and then examined who was left to be treated. METHODS: Using data from the Canadian HIV-HCV Coinfection Cohort, we applied a difference-in-differences approach. Changes in treatment initiation rates following the removal of fibrosis stage restrictions were assessed using a negative binomial regression with generalized estimating equations. The policy change was then specifically assessed among people who inject drugs (PWID). We then identified the characteristics of participants who remained to be treated using a modified Poisson regression. RESULTS: Between 2010–2018, there were a total of 585 HCV initiations among 1130 eligible participants. After removing fibrosis stage restrictions, DAA initiations increased by 1.8-fold (95% confidence interval [CI] 1.3–2.4) controlling for time-invariant differences and secular trends. Among PWID the impact appeared even stronger, with an adjusted incidence rate ratio of 3.6 (95% CI 1.8–7.4). However, this increased treatment uptake was not sustained. At 1 year following universal access, treatment rates declined to 0.8 (95% CI .5–1.1). Marginalized participants (PWID and those of indigenous ethnicity) and those disengaged from care were more likely to remain HCV RNA positive. CONCLUSIONS: After the removal of fibrosis restrictions, HCV treatment initiations nearly doubled immediately, but this treatment rate was not sustained. To meet the World Health Organization elimination targets, the minimization of structural barriers and adoption of tailored interventions are needed to engage and treat all vulnerable populations.
format Online
Article
Text
id pubmed-7353326
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-73533262020-07-15 Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake Among People Living With Human Immunodeficiency Virus Saeed, Sahar Strumpf, Erin Moodie, Erica E M Wong, Leo Cox, Joseph Walmsley, Sharon Tyndall, Mark Cooper, Curtis Conway, Brian Hull, Mark Martel-Laferriere, Valerie Gill, John Wong, Alexander Vachon, Marie-Louise Klein, Marina B Clin Infect Dis Articles and Commentaries BACKGROUND: High costs of direct-acting antivirals (DAAs) have led health-care insurers to limit access worldwide. Using a natural experiment, we evaluated the impact of removing fibrosis stage restrictions on hepatitis C (HCV) treatment initiation rates among people living with human immunodeficiency virus (HIV), and then examined who was left to be treated. METHODS: Using data from the Canadian HIV-HCV Coinfection Cohort, we applied a difference-in-differences approach. Changes in treatment initiation rates following the removal of fibrosis stage restrictions were assessed using a negative binomial regression with generalized estimating equations. The policy change was then specifically assessed among people who inject drugs (PWID). We then identified the characteristics of participants who remained to be treated using a modified Poisson regression. RESULTS: Between 2010–2018, there were a total of 585 HCV initiations among 1130 eligible participants. After removing fibrosis stage restrictions, DAA initiations increased by 1.8-fold (95% confidence interval [CI] 1.3–2.4) controlling for time-invariant differences and secular trends. Among PWID the impact appeared even stronger, with an adjusted incidence rate ratio of 3.6 (95% CI 1.8–7.4). However, this increased treatment uptake was not sustained. At 1 year following universal access, treatment rates declined to 0.8 (95% CI .5–1.1). Marginalized participants (PWID and those of indigenous ethnicity) and those disengaged from care were more likely to remain HCV RNA positive. CONCLUSIONS: After the removal of fibrosis restrictions, HCV treatment initiations nearly doubled immediately, but this treatment rate was not sustained. To meet the World Health Organization elimination targets, the minimization of structural barriers and adoption of tailored interventions are needed to engage and treat all vulnerable populations. Oxford University Press 2020-07-15 2019-08-28 /pmc/articles/PMC7353326/ /pubmed/31504327 http://dx.doi.org/10.1093/cid/ciz833 Text en © The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Articles and Commentaries
Saeed, Sahar
Strumpf, Erin
Moodie, Erica E M
Wong, Leo
Cox, Joseph
Walmsley, Sharon
Tyndall, Mark
Cooper, Curtis
Conway, Brian
Hull, Mark
Martel-Laferriere, Valerie
Gill, John
Wong, Alexander
Vachon, Marie-Louise
Klein, Marina B
Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake Among People Living With Human Immunodeficiency Virus
title Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake Among People Living With Human Immunodeficiency Virus
title_full Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake Among People Living With Human Immunodeficiency Virus
title_fullStr Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake Among People Living With Human Immunodeficiency Virus
title_full_unstemmed Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake Among People Living With Human Immunodeficiency Virus
title_short Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake Among People Living With Human Immunodeficiency Virus
title_sort eliminating structural barriers: the impact of unrestricted access on hepatitis c treatment uptake among people living with human immunodeficiency virus
topic Articles and Commentaries
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7353326/
https://www.ncbi.nlm.nih.gov/pubmed/31504327
http://dx.doi.org/10.1093/cid/ciz833
work_keys_str_mv AT saeedsahar eliminatingstructuralbarrierstheimpactofunrestrictedaccessonhepatitisctreatmentuptakeamongpeoplelivingwithhumanimmunodeficiencyvirus
AT strumpferin eliminatingstructuralbarrierstheimpactofunrestrictedaccessonhepatitisctreatmentuptakeamongpeoplelivingwithhumanimmunodeficiencyvirus
AT moodieericaem eliminatingstructuralbarrierstheimpactofunrestrictedaccessonhepatitisctreatmentuptakeamongpeoplelivingwithhumanimmunodeficiencyvirus
AT wongleo eliminatingstructuralbarrierstheimpactofunrestrictedaccessonhepatitisctreatmentuptakeamongpeoplelivingwithhumanimmunodeficiencyvirus
AT coxjoseph eliminatingstructuralbarrierstheimpactofunrestrictedaccessonhepatitisctreatmentuptakeamongpeoplelivingwithhumanimmunodeficiencyvirus
AT walmsleysharon eliminatingstructuralbarrierstheimpactofunrestrictedaccessonhepatitisctreatmentuptakeamongpeoplelivingwithhumanimmunodeficiencyvirus
AT tyndallmark eliminatingstructuralbarrierstheimpactofunrestrictedaccessonhepatitisctreatmentuptakeamongpeoplelivingwithhumanimmunodeficiencyvirus
AT coopercurtis eliminatingstructuralbarrierstheimpactofunrestrictedaccessonhepatitisctreatmentuptakeamongpeoplelivingwithhumanimmunodeficiencyvirus
AT conwaybrian eliminatingstructuralbarrierstheimpactofunrestrictedaccessonhepatitisctreatmentuptakeamongpeoplelivingwithhumanimmunodeficiencyvirus
AT hullmark eliminatingstructuralbarrierstheimpactofunrestrictedaccessonhepatitisctreatmentuptakeamongpeoplelivingwithhumanimmunodeficiencyvirus
AT martellaferrierevalerie eliminatingstructuralbarrierstheimpactofunrestrictedaccessonhepatitisctreatmentuptakeamongpeoplelivingwithhumanimmunodeficiencyvirus
AT gilljohn eliminatingstructuralbarrierstheimpactofunrestrictedaccessonhepatitisctreatmentuptakeamongpeoplelivingwithhumanimmunodeficiencyvirus
AT wongalexander eliminatingstructuralbarrierstheimpactofunrestrictedaccessonhepatitisctreatmentuptakeamongpeoplelivingwithhumanimmunodeficiencyvirus
AT vachonmarielouise eliminatingstructuralbarrierstheimpactofunrestrictedaccessonhepatitisctreatmentuptakeamongpeoplelivingwithhumanimmunodeficiencyvirus
AT kleinmarinab eliminatingstructuralbarrierstheimpactofunrestrictedaccessonhepatitisctreatmentuptakeamongpeoplelivingwithhumanimmunodeficiencyvirus
AT eliminatingstructuralbarrierstheimpactofunrestrictedaccessonhepatitisctreatmentuptakeamongpeoplelivingwithhumanimmunodeficiencyvirus